Viral surveillance using PCR during treatment of AML and ALL.
Stephanie B DixonAdam LaneMaureen M O'BrienKaren C BurnsJennifer L ManginoErin H BreeseMichael J AbsalonJohn P PerentesisChristine L PhillipsPublished in: Pediatric blood & cancer (2017)
Patients with ALL were more susceptible than those with AML to viral reactivation that was persistent or resulted in treatment. Patients with relapsed ALL, refractory ALL, or infantile ALL are most likely to benefit from asymptomatic screening for CMV and adenovirus. International patients are at higher risk for reactivation and may merit screening. EBV reactivation was not significant and does not warrant screening.
Keyphrases
- acute myeloid leukemia
- end stage renal disease
- sars cov
- diffuse large b cell lymphoma
- ejection fraction
- newly diagnosed
- chronic kidney disease
- public health
- epstein barr virus
- acute lymphoblastic leukemia
- allogeneic hematopoietic stem cell transplantation
- patient reported outcomes
- replacement therapy
- smoking cessation
- real time pcr